Seegene Medical Foundation, a specialized medical institution in disease testing, announced on the 19th that it has jointly developed a disease prediction genetic test called 'SeeMyGene' with the Seoul National University Institute of Genomic Medicine.


SeeMyGene analyzes genomic information based on next-generation sequencing (NGS). Seegene Medical Foundation and the Seoul National University Institute of Genomic Medicine applied medically validated genetic variants to the test using numerous research papers and clinical data. In addition, key single nucleotide polymorphisms (SNPs) that reflect the genetic characteristics of East Asians and Koreans were carefully selected to enhance analysis accuracy.

Seegene Medical Foundation

Seegene Medical Foundation

View original image

SeeMyGene is a disease prediction genetic testing solution that precisely analyzes individual genetic information to pre-identify genetic associations with specific diseases. Unlike general health checkups that assess current health status, it helps with early prevention, proper lifestyle management, and the establishment of regular examination plans by analyzing each individual's genetic disease susceptibility.


The test results present the examinee's genetic risk score by comparing it with East Asian and Korean data, providing a rank converted to percentiles, disease risk levels, and disease risk rates. Based on these results, four levels of genetic risk management indicators are offered: standard management, interest management, cautionary management, and intensive management.


The test items center around major disease groups such as cancer, cardiovascular and cerebrovascular diseases, and metabolic diseases. For cancer, the items include thyroid cancer, lung cancer, stomach cancer, and colorectal cancer for both men and women, with breast cancer added for women and prostate cancer for men. Additionally, it comprehensively assesses individual genetic risk by analyzing three types of cardiovascular and cerebrovascular diseases—cerebral aneurysm, stroke, and myocardial infarction—as well as metabolic diseases such as metabolic syndrome, hypertension, diabetes, and dyslipidemia.


Notably, SeeMyGene not only quantifies the genetic risk for each disease but also suggests health management directions based on the results. For example, if an individual is found to have a high genetic risk for a specific disease, the test provides guidance on the need for regular check-ups, dietary improvements, smoking cessation, moderation of alcohol consumption, and exercise. If the examinee has a family history or existing risk factors, they are advised to consult with medical professionals to establish a more systematic management plan.



A representative from Seegene Medical Foundation stated, "Through SeeMyGene, our goal is to identify individual genetic disease susceptibility more precisely—something difficult to determine with standard health checkups alone—and to establish a prevention-oriented health management system." The representative added, "Furthermore, based on our joint development with the Seoul National University Institute of Genomic Medicine, we plan to continuously update the disease categories and management measures for prevention, as well as incorporate accumulated research data and clinical evidence to further advance genome-based testing services tailored to Koreans."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing